




## Rat IgG Isotype Control

Cat. No.	Format	Size
0108-01	Purified (UNLB)	10 mg
0108-02	Fluorescein (FITC)	0.5 mg
0108-09	R-phycoerythrin (PE)	0.1 mg
0108-11	Allophycocyanin (APC)	0.1 mg
0108-14	Low Endotoxin, Azide-Free (LE/AF)	0.5 mg



ELISA plate was coated with serially diluted Rat IgG-UNLB (SB Cat. No. 0108-01). Immunoglobulin was detected with Goat Anti-Rat IgG-BIOT (SB Cat. No. 3030-08) and Mouse Anti-Rat IgM-BIOT (SB Cat. No. 3080-08) followed by Streptavidin-HRP (SB Cat No. 7100-05) and quantified.

### Description

<b>Isotype</b>	Rat IgG
<b>Source</b>	Normal rat serum

### Applications

Quality tested applications include –

FC<sup>3-9,16</sup>  
 ELISA<sup>1,2</sup>  
 FLISA

Other referenced applications include –

IHC-PS<sup>10,17</sup>  
 IHC-FS<sup>18</sup>  
 ICC<sup>11,19</sup>  
 Block<sup>12</sup>  
*In vivo* control<sup>13-15,20,21</sup>

### Working Dilutions

<b>Flow Cytometry</b>	FITC conjugate	≤ 1 µg/10 <sup>6</sup> cells
	PE and APC conjugates	≤ 0.1 µg/10 <sup>6</sup> cells

For flow cytometry, the suggested use of these reagents is in a final volume of 100 µL

**Other Applications** Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.

**For Research Use Only. Not for Diagnostic or Therapeutic Use.**

## Handling and Storage

---

- The purified (UNLB) IgG is supplied as 10 mg of purified immunoglobulin in 2.0 mL of borate buffered saline, pH 8.2. *No preservatives or amine-containing buffer salts added.* Store at 2-8°C.
- The fluorescein (FITC) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN<sub>3</sub>. Store at 2-8°C.
- The R-phycoerythrin (PE) and allophycocyanin (APC) conjugates are supplied as 0.1 mg in 1.0 mL of PBS/NaN<sub>3</sub> and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- The low endotoxin, azide-free (LE/AF) antibody is supplied as 0.5 mg purified immunoglobulin in 1.0 mL of PBS. **Aliquot and store at or below -20°C.**
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

## Warning

---

Some reagents contain sodium azide. Please refer to product specific SDS.

## References

---

1. Doymaz MZ, Rouse BT. Herpetic stromal keratitis: an immunopathologic disease mediated by CD4+ T lymphocytes. *Invest Ophthalmol Vis Sci.* 1992;33:2165-73. (ELISA)
2. Swanson CL, Wilson TJ, Strauch P, Colonna M, Pelanda R, Torres RM. Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response. *J Exp Med.* 2010;207:1485-1500. (ELISA)
3. Garbe A, Buck J, Hämmerling U. Retinoids are important cofactors in T cell activation. *J Exp Med.* 1992;176:109-17. (FC)
4. Mierke CT, Ballmaier M, Werner U, Manns MP, Welte K, Bischoff SC. Human endothelial cells regulate survival and proliferation of human mast cells. *J Exp Med.* 2000;192:801-11. (FC)
5. Abernethy NJ, Hagan C, Tan PL, Watson JD. Dysregulated expression of CD69 and IL-2 receptor  $\alpha$  and  $\beta$  chains on CD8+ T lymphocytes in flaky skin mice. *Immunol Cell Biol.* 2000;78:596-602. (FC)
6. Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V, et al. Phenotype, localization, and mechanism of suppression of CD4+CD25+ human thymocytes. *J Exp Med.* 2002;196:379-87. (FC)
7. Cosmi L, Liotta F, Lazzeri E, Francalanci M, Angeli R, Mazzinghi B, et al. Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. *Blood.* 2003;102:4107-14. (FC)
8. Welner R, Swett DJ, Pelsue SC. Age-related loss of bone marrow pre-B- and immature B-lymphocytes in the autoimmune-prone flaky skin mutant mice. *Autoimmunity.* 2005;38:399-408. (FC)
9. Abbasi S, Shin D, Beaty N, Masiuk M, Chen S, Gonzalez-Garcia I, et al. Characterization of monoclonal antibodies to the plasma cell alloantigen ENPP1. *Hybridoma.* 2011;30:11-17. (FC)
10. Almholt K, Lund LR, Rygaard J, Nielsen BS, Danø K, Rømer J, et al. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. *Int J Cancer.* 2005;113:525-32. (IHC-PS)
11. Lu DP, Tian L, O'Neill C, King NJ. Regulation of cellular adhesion molecule expression in murine oocytes, peri-implantation and post-implantation embryos. *Cell Res.* 2002;12:373-83. (ICC)
12. Pepin AC, Tandon R, Cattori V, Niederer E, Riond B, Willi B, et al. Cellular segregation of feline leukemia provirus and viral RNA in leukocyte subsets of long-term experimentally infected cats. *Virus Res.* 2007;127:9-16. (Block)
13. Broudy VC, Lin NL, Priestley GV, Nocka K, Wolf NS. Interaction of stem cell factor and its receptor c-kit mediates lodgment and acute expansion of hematopoietic cells in the murine spleen. *Blood.* 1996;88:75-81. (*In vivo* control)
14. Cheng M, Nguyen M, Fantuzzi G, Koh TJ. Endogenous interferon- $\gamma$  is required for efficient skeletal muscle regeneration. *Am J Physiol Cell Physiol.* 2008;294:C1183-91. (*In vivo* control)
15. Ma Y, Zhang X, Bao H, Mi S, Cai W, Yan H, et al. Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice. *PLoS One.* 2012;7(7):e40763. (*In vivo* control)
16. Mattsson N, Duzevik EG, Pelsue SC. Expansion of CD22<sup>lo</sup> B cells in the spleen of autoimmune-prone flaky skin mice. *Cell Immunol.* 2005;234:124-32. (FC)
17. Yukami T, Hasegawa M, Matsushita Y, Fujita T, Matsushita T, Horikawa M, et al. Endothelial selectins regulate skin wound healing in cooperation with L-selectin and ICAM-1. *J Leukoc Biol.* 2007;82:519-31. (IHC-PS)
18. Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, et al. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. *Am J Pathol.* 2008;172:1650-63. (IHC-FS)
19. Hauser SP, Waldron JA, Upuda KB, Lipschitz DA. Morphological characterization of stromal cell types in hematopoietically active long-term murine bone marrow cultures. *J Histochem Cytochem.* 1995;43:371-9. (ICC)
20. Milbauer LC, Enenstein JA, Roney M, Solovey A, Bodempudi V, Nichols TC, et al. Blood outgrowth endothelial cell migration and trapping in vivo: a window into gene therapy. *Transl Res.* 2009;153:179-89. (*In vivo* control)
21. Saino O, Taguchi A, Nakagomi T, Nakano-Doi A, Kashiwamura S, Doe N, et al. Immunodeficiency reduces neural stem/progenitor cell apoptosis and enhances neurogenesis in the cerebral cortex after stroke. *J Neurosci Res.* 2010;88:2385-97. (*In vivo* control)